Community metaproteomics to establish functional responses within the oral microbiome

社区宏蛋白质组学用于建立口腔微生物组内的功能反应

• 批准号: 2741195
• 金额: --
• 依托单位: University of Sheffield
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2741195
• 关键词: Community; metaproteomics; establish; functional; responses

A healthy oral microbiome is essential to maintaining oraland systemic health. Oral diseases cost the NHS £billions while the oralhealthcare market is also worth £billions. However, understanding how oralproducts affect the composition and function of the oral microbiota is weak.Our project will use cutting-edge metaproteomics techniques to establishfunctional changes in the microbiome in response to commonly used oralproduct additives. This will be in combination with rapid nanopore 16Smicrobiome sequencing, and focus initially on Chlorehexidine (CHX) plus anovel active developed at GSK (placement work).CHX is a common antimicrobial in daily mouthwashes, with continued usagealtering the microbiome and affecting blood-pressure modifying compounds2022 entry WR BBSRC DTP CASE Form A-FINAL 2021-07-16 Page 2 of 15accessible manner to appeal to a widerange of applicants.(e.g. nitrite). In addition, CHX use can induce resistance to antibiotics insome bacteria.Our team, Stafford + GSK, have developed techniques for growth ofmicrobial communities in vitro, and oral specific 16S Nanopore microbiomeanalyses. We also focussed on virulence determinants (e.g.protease/glycosidase) in these communities. The data and techniquesdeveloped will allow improvement and design of future actives byGSK-consumer healthcare

健康的口腔微生物群对维持口腔和全身健康至关重要。口腔疾病花费了NHS数十亿英镑，而口腔保健市场也价值数十亿英镑。然而，了解口服产品如何影响口腔微生物区系的组成和功能是薄弱的。我们的项目将使用尖端的代谢蛋白质组学技术来建立微生物组的功能变化，以响应常用的口服产品添加剂。这将与纳米孔16S微生物组快速测序相结合，最初重点放在GSK开发的氯己定(CHX)和阿诺韦活性(贴片工作)上。CHX是日常洗口水中的一种常见抗菌剂，继续使用该抗菌剂会影响微生物群并影响血压调节化合物2022条目WR BSRC DTP案例表格A-Final 2021-07-16第15页，以方便的方式吸引更广泛的申请者(例如亚硝酸盐)。此外，CHX的使用会导致一些细菌对抗生素产生抗药性。我们的团队Stafford+GSK已经开发了微生物群落的体外生长技术和口服16S纳米孔微生物分析。我们还重点研究了这些群落中的毒力决定因素(如蛋白酶/糖苷酶)。开发的数据和技术将允许GSK改进和设计未来的活动-消费者保健